Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 15/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 15/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 15/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 14/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 12/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18081172 | 1.00 | CHRNB2 (0.46) | CHRNB2CHRNA3CHRNA4CHRNB4SMN1; SMN2 | |
| SCHEMBL1481267 | 1.00 | CHRNB2 (0.46) | CHRNB2CHRNA3CHRNA4CHRNB4SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1480990 | 0.98 | CHRNB2 (0.45) | CHRNB2CHRNA3CHRNA4CHRNB4SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL15956717 | 0.98 | CHRNB2 (0.45) | CHRNB2CHRNA3CHRNA4CHRNB4SMN1; SMN2 | |
| SCHEMBL7050116 | 0.88 | HTR2C (0.46) | CHRNB2CHRNA3CHRNA4CHRNB4SMN1; SMN2 | |
| SCHEMBL28949604 | 0.80 | HTR2C (0.46) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL26334441 | 0.80 | HTR2C (0.46) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL6368277 | 0.80 | HTR2C (0.46) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL2379324 | 0.80 | HTR2C (0.46) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL2846979 | 0.80 | HTR2C (0.46) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| US-11407719-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2022-08-09 | — | — | US | disclosed |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2021-03-11 | — | — | US | disclosed |
| US-10882828-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2021-01-05 | — | — | US | disclosed |
| EP-3313397-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2019-04-25 | — | — | US | disclosed |
| US-10221178-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10131640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2018-11-20 | — | — | US | disclosed |
| US-20180141947-A1 | Purine Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
| EP-1632477-B1 | BENZAMIDE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2017-03-01 | — | — | EP | disclosed |
| EP-2532667-A1 | Deazapurines useful as inhibitors of janus kinases | Vertex Pharmaceuticals Incorporated (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-1931674-B1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMA (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | disclosed |
| EP-2408454-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | disclosed |
| US-7521441-B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1931674-A2 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | Vertex Pharmceuticals Incorporated (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070270406-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-22 | — | — | US | disclosed |
| US-20070207995-A1 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-06 | — | — | US | disclosed |
| WO-2007041130-A2 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407719-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | CHRNB2 2672/4885CHRNA3 1862/4885CHRNA4 1993/4885 |
| US-10882828-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | CHRNB2 2672/4885CHRNA3 1862/4885CHRNA4 1993/4885 |
| US-20070270406-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | CHRNB2 4197/4885CHRNA3 3926/4885CHRNA4 4180/4885 |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | CHRNB2 2672/4885CHRNA3 1862/4885CHRNA4 1993/4885 |
| US-10131640-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | CHRNB2 2672/4885CHRNA3 1862/4885CHRNA4 1993/4885 |
| US-10221178-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PI4KA | CHRNB2 1216/4885CHRNA3 820/4885CHRNA4 1196/4885 |
| US-20070207995-A1 | Deazapurines useful as inhibitors of Janus kinases | JAK1, JAK3, JAK2 | CHRNB2 4878/4885CHRNA3 4837/4885CHRNA4 4866/4885 |
| US-20180141947-A1 | Purine Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | PIK3CD, PIK3CA, PI4KA | CHRNB2 1216/4885CHRNA3 820/4885CHRNA4 1196/4885 |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | CHRNB2 2564/4885CHRNA3 1693/4885CHRNA4 1848/4885 |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | CHRNB2 2564/4885CHRNA3 1693/4885CHRNA4 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.